
The episode discusses the potential of long read sequencing in clinical settings for acute leukemia patients.
Acute leukemia patients often wait days or even weeks for the full battery of molecular tests needed to guide treatment decisions. Dr. Parth Shah from Dartmouth believes long read sequencing can dramatically shorten that timeline. In this episode, Shah joins Agilent's Rita Shaknovich and Oxford Nanopore's Claire Attwooll to discuss some details of how long reads are beginning to move from research applications into routine clinical testing. Along the way, we explore the role of targeted enrichment, quality control, automation, and informatics in making these workflows practical for real-world laboratories. For Shah, the field has reached an inflection point. After more than a decade of development, he argues that long reads are finally positioned to make the leap into clinical genomics. “As we ask more complex questions of human biology, long read is probably going to be the best ammunition that we have,” he says. His team at Dartmouth has already demonstrated the potential in acute myeloid leukemia, where a long-read workflow can now generate a comprehensive molecular profile within 24 hours rather than the weeks often required by conventional testing. Shaknovich emphasizes that…
Host: Theral Timpson
Guests: Dr. Parth Shah, Rita Shaknovich, Claire Attwooll
Organizations: Dartmouth, Agilent, Oxford Nanopore, acute myeloid leukemia
Explore listener stats, chart rankings, contacts and more on the Mendelspod Podcast podcast page.